According to filings with the U.S. Securities and Exchange Commission, Kytopen is raising up to $8,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Chiu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kytopen
Kytopen, an MIT spin-out, is a transformative biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development and manufacturing phases of cell engineering. Flowfect, a gentle, non-viral delivery method unlocks new therapeutic approaches, by engineering immune cells with minimal disruption, preserving the functionality and viability of human cells and enhancing the cells biology. The Flowfect platform accelerates therapies from the bench to clinical through flexibility and scalability, which drives higher cell yields, faster approvals, and better outcomes from potentially curative cell-based treatments. Kytopens goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to increase access to many more patients.

To learn more about Kytopen, visit http://kytopen.com/

Contact:
Michael Chiu, Chief Executive Officer
617-299-1688
https://www.linkedin.com/in/michaelachiu/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.